Phendimetrazine 사용으로 유발된 정신증적 장애 및 의존 1예 = A Case of Phendimetrazine Induced-Psychotic Disorder and Dependence

국문 초록 (Abstract)

식욕억제제의 대부분은 amphetamine 계통으로 정신증적증상 및 의존의 위험성이 있다. 본 증례의 25세 여성은 phendimetrazine을복용한 이후 정신증적 증상이 발생하여 입원치료를 했지만, 퇴원 후에 다시 phendimetrazine을 복용하게되었다. 결국 정신증적 증상이 재발하였고 더불어 약물에 대한 금단증상과 갈망을 나타내어 phendimetrazine에 대한 의존을 확인할 수 있었다. 최근 국내에서 식욕억제제의 사용이증가하고 있으며, 이러한 부작용의 발생은 더 증가하리라 예상된다. 이러한 위험성을 충분히 고려하여 식욕억제제 처방과 사용에 대한 세심한 주의와 엄격한 지침이 필요하겠다.

다국어 초록 (Multilingual Abstract)

Phendimetrazine and related amphetamine-like compounds are used widely as appetite suppressants in Korea. We report on a patient who developed psychotic disorder and dependence while using phendimetrazine. A 25-year-old female with no psychiatric history began experiencing hallucination of bugs after using phendimetrazine for weight loss for five months. She was admitted and the drug was stopped. Three days later, her psychotic symptoms had subsided and she returned home. Two months after discharge, against medical advice, she returned to a clinic to obtain phendimetrazine for its anorectic effect. She continued using phendimetrazine because she had developed withdrawal symptoms and experienced cravings for it. Within two months of restarting the drug, she had developed paranoid delusions, auditory and olfactory hallucinations. She was readmitted, and was confirmed to have a dependence on phendimetrazine. This case provides a warning that amphetamine-related anorectics can cause psychotic disorder and dependence.

참고문헌 (Reference)

1 김경곤, "비만의 약물 요법" 대한의사협회 54 (54): 409-418, 2011

2 송보경, "비만 치료제 소비자 행태조사 및 효율적 사용방안 연구" 소비자시민모임, 식품의약품안정청 2008

3 "Vienna: International Narcotic Control Board Online Resources"

4 "United States Food and Drug Administration"

5 Kim SM, "Treatment of obesity with drugs" 47 : 361-368, 2004

6 "The Organisation for Economic Co-operation and Development"

7 Murray PA, "Sympathomimetic drug-induced psychosis" 54 : 21-23, 1964

8 Stahl SM, "Stahl’s essential psychopharmacology: neuroscientific basis and practical applications" Cambridge University Press 982-983, 2008

9 "Phentermine: psychosis: 4 case reports"

10 Cleare AJ, "Phentermine, psychosis, and family history" 16 : 470-471, 1996

11 Devan GS, "Phentermine and psychosis" 156 : 442-443, 1990

12 Rothman RB, "Phentermine and fenfluramine. Preclinical studies in animal models of cocaine addiction" 844 : 59-74, 1998

13 이종민, "Phendimetrazine 사용으로 유발된 정신증적 장애 2예" 대한정신약물학회 21 (21): 95-98, 2010

14 Nathan PJ, "Neuropsychiatric adverse effects of centrally acting antiobesity drugs" 17 : 490-505, 2011

15 "Ministry of food and drug safety"

16 Glazer G, "Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety" 161 : 1814-1824, 2001

17 Shannon PJ, "Letter: Fenfluramine and psychosis" 3 : 576-, 1974

18 Rothman RB, "Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain" 447 : 51-57, 2002

19 "European Medicines Agency"

20 Brooke D, "Diethylpropion hydrochloride-induced psychosis" 152 : 572-573, 1988

21 Carney MW, "Diethylpropion and psychosis" 11 : 183-188, 1988

22 Hoffman BF, "Diet pill psychosis" 116 : 351-355, 1977

23 강준구, "Anti-Obesity Drugs: A Review about Their Effects and Safety" 대한당뇨병학회 36 (36): 13-25, 2012

24 Rubin RT, "Acute psychotic reaction following ingestion of phentermine" 120 : 1124-1125, 1964

25 McEvoy GK, "AHFS drug information 89" American Society of Hospital Pharmacists 1989

26 Kim SH, "A case of organic hallucinous following phendimetrazine(Fringar@) abuse" 31 : 1119-1122, 1992

27 Landau D, "A case of demand ischemia from phendimetrazine" 1 : 105-, 2008